ABN 16 165 160 841 Amplia Therapeutics Limited ACN 165 160 841 Notice of Annual General Meeting and Explanatory Statement 2026 Annual Report: https://ampliatx.com/reports NOTICE is given that the annual...
Amplia Therapeutics: Notice of Annual General Meeting/Proxy Form
Filed with ASX · · 31 pages · English
Release
Amplia Therapeutics Ltd. on 6ix
Earlier from Amplia Therapeutics
- Amplia Announces Publication of New FAK Inhibitor Patent Application
- Amplia Announces Appointment of Brett Carter to Board
- Amplia Announces Changes to Board’s Leadership Roles
- Following Significant Advances at ASCO, Amplia Therapeutics Provides Letter to Shareholders Highlighting the Potential Opportunities for Combination with KRAS Inhibition in Pancreatic Cancer
- Preliminary Final Report and Annual Report YE 31 March 2026
Later from Amplia Therapeutics
- Quarterly Activities/Appendix 4C Cash Flow Report
- Scientific Paper Studies of narmafotinib - Pancreatic Cancer
- Scientific Paper Detailing Preclinical Studies of Narmafotinib in Pancreatic Cancer Now Online
- Amplia signs Collaboration and Supply Agreement with Lilly
- Bioshares Biotech Summit Presentation
Follow Amplia Therapeutics into a list and get an email when it puts out news.
Follow Amplia Therapeutics